Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 114868
1. Paydar I, Pepin A, Cyr RA, King J, Yung TM, Bullock EG, Lei S, Satinsky A, Harter KW, Suy S, Dritschilo A, Lynch JH, Kole TP, Collins SP: Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity. Front Oncol; 2017;7:5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity.
  • BACKGROUND: Recent data suggest that intensity-modulated radiation therapy (IMRT) plus brachytherapy boost for unfavorable prostate cancer provides improved biochemical relapse-free survival over IMRT alone.
  • MATERIALS AND METHODS: Between March 2008 and September 2012, patients with prostate cancer were treated with robotic SBRT (19.5 Gy in three fractions) followed by fiducial-guided IMRT (45-50.4 Gy) on an institutional protocol.
  • Toxicity was prospectively graded using the common terminology criteria for adverse events version 4.0 (CTCAEv.4) at the start of and at 1- to 6-month intervals after therapy.
  • Future studies should compare cancer control, quality of life, and toxicity with other treatment modalities for patients with high-risk prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Technol Cancer Res Treat. 2010 Oct;9(5):453-62 [20815416.001]
  • [Cites] Front Oncol. 2016 May 06;6:114 [27200300.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):150-4 [16111583.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):937-9 [26530768.001]
  • [Cites] Radiother Oncol. 1998 Mar;46(3):285-95 [9572622.001]
  • [Cites] J Urol. 2015 Dec;194(6):1624-30 [26165583.001]
  • [Cites] Radiat Oncol. 2016 Jan 21;11:8 [26792201.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):125-9 [22330997.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):751-8 [20207506.001]
  • [Cites] Technol Cancer Res Treat. 2010 Dec;9(6):575-82 [21070079.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1192-9 [15718316.001]
  • [Cites] Radiother Oncol. 2012 Jul;104(1):114-8 [22727264.001]
  • [Cites] Radiat Oncol. 2013 Mar 13;8:58 [23497695.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1048-55 [15001244.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):1990-6 [16648499.001]
  • [Cites] Urology. 2000 Dec 20;56(6):899-905 [11113727.001]
  • [Cites] Acta Oncol. 2005;44(3):265-76 [16076699.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):316-27 [12023135.001]
  • [Cites] Cancer. 2015 Jul 15;121(14):2422-30 [25847819.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):999-1007 [16750320.001]
  • [Cites] Urology. 2000 Mar;55(3):382-6 [10699615.001]
  • [Cites] Radiat Oncol. 2013 Jan 31;8:30 [23369294.001]
  • [Cites] Radiother Oncol. 2012 May;103(2):217-22 [22341794.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):877-82 [21300474.001]
  • [Cites] Cancer. 2013 Feb 1;119(3):681-90 [22893254.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):383-7 [18947938.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):67-74 [17765406.001]
  • [Cites] Cancer. 1999 Jun 15;85(12):2630-7 [10375112.001]
  • [Cites] J Urol. 2016 Jun;195(6):1811-6 [26778712.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):679-85 [22954770.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1443-53 [27325475.001]
  • [Cites] Radiother Oncol. 2000 Jan;54(1):11-9 [10719695.001]
  • [Cites] Radiat Oncol. 2014 Jan 01;9:1 [24382205.001]
  • [Cites] Br J Radiol. 2015 Oct;88(1054):20140736 [26235142.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2015 Aug 1;92 (5):971-7 [26054865.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):932-8 [24113055.001]
  • [Cites] Front Oncol. 2014 Oct 31;4:278 [25401085.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 2):S21-5; discussion S26-7 [14610406.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):646-55 [17531401.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1306-16 [15817332.001]
  • [Cites] Radiat Oncol. 2014 Dec 12;9:277 [25497602.001]
  • [Cites] Radiother Oncol. 2009 May;91(2):232-6 [19097660.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5366-73 [18048817.001]
  • [Cites] JAMA. 2005 Sep 14;294(10):1233-9 [16160131.001]
  • [Cites] Front Oncol. 2015 Sep 01;5:194 [26389077.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):184-91 [12694837.001]
  • [Cites] J Urol. 2007 Jan;177(1):123-7; discussion 127 [17162020.001]
  • (PMID = 28224113.001).
  • [Journal-full-title] Frontiers in oncology
  • [ISO-abbreviation] Front Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; CyberKnife / IMRT / SBRT / common terminology criteria / prostate cancer
  •  go-up   go-down


2. Williams F, Imm KR, Colditz GA, Housten AJ, Yang L, Gilbert KL, Drake BF: Physician role in physical activity for African-American males undergoing radical prostatectomy for prostate cancer. Support Care Cancer; 2017 Apr;25(4):1151-1158

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Physician role in physical activity for African-American males undergoing radical prostatectomy for prostate cancer.
  • PURPOSE: Physical activity is recognized as a complementary therapy to improve physical and physiological functions among prostate cancer survivors.
  • Little is known about communication between health providers and African-American prostate cancer patients, a high risk population, regarding the health benefits of regular physical activity on their prognosis and recovery.
  • This study explores African-American prostate cancer survivors' experiences with physical activity prescription from their physicians.
  • METHODS: Three focus group interviews were conducted with 12 African-American prostate cancer survivors in May 2014 in St. Louis, MO.
  • These findings highlight the importance of physical activity communication and prescription for prostate cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27999951.001).
  • [ISSN] 1433-7339
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; African-American / Physical activity / Physician / Prescription/communication / Prostate cancer / Survivor
  •  go-up   go-down


3. Kuusk T, Pulliainen K, Vaarala MH: External beam radiation for the treatment of castration-resistant prostate cancer following primary hormonal therapy with androgen ablation: Analysis and outcome of 21 patients. Mol Clin Oncol; 2017 Mar;6(3):428-432
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] External beam radiation for the treatment of castration-resistant prostate cancer following primary hormonal therapy with androgen ablation: Analysis and outcome of 21 patients.
  • Patients who undergo early androgen-deprivation therapy for prostate cancer may eventually develop castration-resistant prostate cancer.
  • However, no optimal treatment for non-metastasized castration-resistant prostate cancer has yet been established.
  • In the present retrospective, single-institutional study, the radiotherapy (RT) outcomes were evaluated in patients who underwent androgen-deprivation therapy for non-metastatic prostate cancer and subsequently developed castration-resistant disease.
  • Following a thorough chart review, the data of 21 patients with castration-resistant prostate cancer who were treated between 2000 and 2010 with external beam radiation therapy (EBRT) at a prostate radiation dose of >45 Gy were evaluated.
  • A total of 18 patients succumbed to the disease during follow-up, with a mean survival of 3 years after RT.
  • Prostate-specific survival time was negatively associated with the Gleason score at diagnosis.
  • The prostate-specific antigen (PSA) concentration prior to RT was a prognostic factor for biochemical recurrence of prostate cancer after RT, as well as for prostate cancer-specific survival.
  • Finally, the multivariate analysis revealed that age, PSA concentration prior to RT and a high Gleason score were independent prognostic factors for prostate cancer-specific survival.
  • Overall, our study findings demonstrated that disease progression was common after EBRT for castration-resistant prostate cancer and that survival was limited.
  • However, young patients and those with low-risk disease at the time of diagnosis may benefit from RT.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Urol. 2015 Sep;68(3):386-96 [25484142.001]
  • [Cites] J Cancer Res Clin Oncol. 2013 Nov;139(11):1955-60 [24057645.001]
  • [Cites] Anticancer Res. 2004 Sep-Oct;24(5B):3141-5 [15510602.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):e205-11 [22342096.001]
  • [Cites] J Urol. 2007 Jun;177(6):2106-31 [17509297.001]
  • [Cites] Int J Urol. 1999 Apr;6(4):187-91 [10226836.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23 (9):1962-8 [15774789.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):759-65 [19327908.001]
  • [Cites] BJU Int. 2009 Nov;104(10):1462-6 [19522869.001]
  • [Cites] Ann Intern Med. 2008 Mar 18;148(6):435-48 [18252677.001]
  • [Cites] Am J Clin Oncol. 2004 Jun;27(3):264-8 [15170145.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1708-14 [16544313.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Nov 1;33(4):907-12 [7591901.001]
  • [Cites] Eur Urol. 2014 Feb;65(2):467-79 [24321502.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2015 Jan;27(1):16-21 [25445554.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):372-9 [15145150.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95 [15663992.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):2918-25 [15860850.001]
  • (PMID = 28451427.001).
  • [ISSN] 2049-9450
  • [Journal-full-title] Molecular and clinical oncology
  • [ISO-abbreviation] Mol Clin Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; prostate cancer / radiation / retrospective chart review
  •  go-up   go-down


Advertisement
4. Chaussy CG, Thüroff S: High-Intensity Focused Ultrasound for the Treatment of Prostate Cancer: A Review. J Endourol; 2017 Apr;31(S1):S30-S37
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-Intensity Focused Ultrasound for the Treatment of Prostate Cancer: A Review.
  • Over the past 25 years, the average life expectancy for men has increased almost 4 years, and the age of prostate cancer detection has decreased an average of 10 years with diagnosis increasingly made at early-stage disease where curative therapy is possible.
  • These changing trends in the age and extent of malignancy at diagnosis have revealed limitations in conventional curative therapies for prostate cancer, including a significant risk of aggressive cancer recurrence, and the risk of long-term genitourinary morbidity and its detrimental impact on patient's quality of life (QOL).
  • Greater awareness of the shortcomings in radical prostatectomy, external radiotherapy, and brachytherapy has prompted the search for alternative curative therapies that offer comparable rates of cancer control and less treatment-related morbidity to better preserve QOL.
  • HIFU is a noninvasive approach that uses precisely delivered ultrasound energy to achieve tumor cell necrosis without radiation or surgical excision.
  • In current urologic oncology, HIFU is used clinically in the treatment of prostate cancer and is under experimental investigation for therapeutic use in multiple malignancies.
  • Clinical research on HIFU therapy for localized prostate cancer began in the 1990s, and there have now been ∼65,000 prostate cancer patients treated with HIFU, predominantly with the Ablatherm (EDAP TMS, Lyon, France) device.
  • Neoadjuvant transurethral resection of the prostate has been combined with HIFU since 2000 to reduce prostate size, facilitate tissue destruction, and to minimize side effects.
  • Advances in imaging technologies are expected to further improve the already superior efficacy and morbidity outcomes, and ongoing investigation of HIFU as a focal therapy in salvage and palliative indications is serving to expand the role of HIFU as a highly versatile noninvasive therapy for prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28355119.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; castration-resistant prostate cancer / high-intensity focused ultrasound (HIFU) / noninvasive focal therapy / prostate cancer therapy
  •  go-up   go-down


5. Giannarini G, Crestani A, Rossanese M, Ficarra V: Multiparametric Magnetic Resonance Imaging Targeted Biopsy for Early Detection of Prostate Cancer: All That Glitters Is Not Gold! Eur Urol; 2017 Jun;71(6):904-906

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiparametric Magnetic Resonance Imaging Targeted Biopsy for Early Detection of Prostate Cancer: All That Glitters Is Not Gold!

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28094057.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] Switzerland
  •  go-up   go-down


6. Chang AR, Park W: Radiotherapy in prostate cancer treatment: results of the patterns of care study in Korea. Radiat Oncol J; 2017 Mar;35(1):25-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy in prostate cancer treatment: results of the patterns of care study in Korea.
  • PURPOSE: The purpose of this study was to describe treatment patterns of radiotherapy (RT) for prostate cancer in Korea.
  • MATERIALS AND METHODS: A questionnaire about radiation treatment technique and principles in 2013 was sent to 83 radiation oncologists and data from 57 hospitals were collected analyzed to find patterns of RT for prostate cancer patients in Korea.
  • RESULTS: The number of patients with prostate cancer treated with definitive RT ranged from 1 to 72 per hospital in 2013.
  • Salvage RT was delivered with findings of consecutive elevations in prostate-specific antigen (PSA), PSA level over 0.2 ng/mL, or clinical recurrence.
  • CONCLUSION: This nationwide patterns of care study suggests that variable radiation techniques and a diverse range of dose fractionation schemes are applied for prostate cancer treatment in Korea.
  • Standard guidelines for RT in prostate cancer need to be developed.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):654-62 [17011444.001]
  • [Cites] Lancet Oncol. 2011 May;12(5):451-9 [21440505.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1056-63 [21147514.001]
  • [Cites] J Urol. 2014 Dec;192(6):1650-6 [24931803.001]
  • [Cites] Cancer Res Treat. 2015 Apr;47(2):127-41 [25761484.001]
  • [Cites] N Engl J Med. 2009 Jun 11;360(24):2516-27 [19516032.001]
  • [Cites] Lancet Oncol. 2014 Sep;15(10):1076-89 [25130995.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2497-504 [18413638.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):646-55 [17531401.001]
  • [Cites] Lancet. 2005 Aug 13-19;366(9485):572-8 [16099293.001]
  • [Cites] Radiat Oncol. 2014 Feb 05;9:47 [24499610.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5366-73 [18048817.001]
  • [Cites] CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29 [24399786.001]
  • [Cites] JAMA. 2005 Sep 14;294(10):1233-9 [16160131.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1723-9 [21493013.001]
  • [Cites] Lancet Oncol. 2005 Nov;6(11):841-50 [16257791.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1243-52 [11483335.001]
  • [Cites] Cancer Res Treat. 2016 Jul;48(3):899-906 [26511804.001]
  • (PMID = 28292006.001).
  • [ISSN] 2234-1900
  • [Journal-full-title] Radiation oncology journal
  • [ISO-abbreviation] Radiat Oncol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Keywords] NOTNLM ; Patterns of care / Prostate cancer / Radiotherapy
  •  go-up   go-down


7. Javanmard B, Hassanzadeh Haddad A, Yaghoobi M, Lotfi B: Diode laser ablation of prostate and channel transurethral resection of prostate in patients with prostate cancer and bladder outlet obstruction symptoms. Urol J; 2014 Jul-Aug;11(4):1788-92
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diode laser ablation of prostate and channel transurethral resection of prostate in patients with prostate cancer and bladder outlet obstruction symptoms.
  • PURPOSE: To evaluate the efficacy of diode laser ablation of prostate for treating lower urinary tract symptoms (LUTS) in patients with locally advanced prostate cancer and comparing results with palli­ative transurethral resection of prostate (pTURP).
  • MATERIALS AND METHODS: Thirty-six known cases of locally advanced prostate cancer with a maximum urinary flow rate (Qmax) of 12 mL per second or less and an International Prostate Symptom Score (IPSS) of 20 or more were included in this study.
  • The first group underwent pTURP and for the second group diode laser ablation of prostate was done.
  • CONCLUSION: Diode laser ablation of prostate and pTURP, both improved significantly IPSS, PVR and Qmax.
  • [MeSH-major] Ablation Techniques / instrumentation. Carcinoma / surgery. Lasers, Semiconductor / therapeutic use. Palliative Care. Prostatic Neoplasms / surgery. Prostatism / surgery. Urinary Bladder Neck Obstruction / surgery
  • [MeSH-minor] Aged. Humans. Length of Stay. Male. Middle Aged. Operative Time. Time Factors. Transurethral Resection of Prostate. Urinary Catheterization. Urodynamics

  • Genetic Alliance. consumer health - Bladder cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25194077.001).
  • [ISSN] 1735-546X
  • [Journal-full-title] Urology journal
  • [ISO-abbreviation] Urol J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Iran
  •  go-up   go-down


8. Bell LJ, Eade T, Kneebone A, Hruby G, Alfieri F, Bromley R, Grimberg K, Barnes M, Booth JT: Initial experience with intra-fraction motion monitoring using Calypso guided volumetric modulated arc therapy for definitive prostate cancer treatment. J Med Radiat Sci; 2017 Mar;64(1):25-34
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial experience with intra-fraction motion monitoring using Calypso guided volumetric modulated arc therapy for definitive prostate cancer treatment.
  • INTRODUCTION: Accurate delivery of radiation while reducing dose to organs at risk is essential in prostate treatment.
  • Three patients had Calypso beacons inserted into their prostate.
  • Prostate rotation was largest in the pitch direction and 28 fractions exceeded the 10° tolerance.
  • [MeSH-major] Dose Fractionation. Movement. Prostatic Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / methods

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 The Authors. Journal of Medical Radiation Sciences published by Wiley Publishing Asia Pty Ltd on behalf of Australian Society of Medical Imaging and Radiation Therapy and New Zealand Institute of Medical Radiation Technology.
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1579-85 [20472357.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1099-105 [17336216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1088-98 [17187940.001]
  • [Cites] Med Phys. 2014 Feb;41(2):020702 [24506591.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):1017-25 [25832692.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):477-83 [23523325.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1097-105 [12128107.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):51-63 [12504036.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):528-34 [16690435.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):682-9 [17398026.001]
  • (PMID = 28263041.001).
  • [ISSN] 2051-3909
  • [Journal-full-title] Journal of medical radiation sciences
  • [ISO-abbreviation] J Med Radiat Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; calypso / implementation / intra-fraction motion / prostate / radiation treatment
  •  go-up   go-down


9. Li J, Hall IJ, Zhao G: Prostate cancer screening decision-making in three states: 2013 behavioral risk factor surveillance system analysis. Cancer Causes Control; 2017 Mar;28(3):235-240
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate cancer screening decision-making in three states: 2013 behavioral risk factor surveillance system analysis.
  • INTRODUCTION: Given the discordant prostate cancer screening recommendations in the United States, shared decision-making (SDM) has become increasingly important.
  • The objectives of this study were to determine who made the final decision to obtain prostate-specific antigen (PSA)-based screening and identify factors associated with the screening decision made by both patients and their health care providers.
  • Only 36% of them made their prostate cancer screening decision jointly with their health care provider.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28210882.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Prostate cancer screening / Prostate-specific antigen test / Shared decision-making
  •  go-up   go-down


10. Henkenberens C, VON Klot CA, Ross TL, Bengel FM, Wester HJ, Katja H, Christiansen H, Derlin T: <sup>68</sup>Ga-PSMA Ligand PET/CT-based Radiotherapy for Lymph Node Relapse of Prostate Cancer After Primary Therapy Delays Initiation of Systemic Therapy. Anticancer Res; 2017 03;37(3):1273-1279
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] <sup>68</sup>Ga-PSMA Ligand PET/CT-based Radiotherapy for Lymph Node Relapse of Prostate Cancer After Primary Therapy Delays Initiation of Systemic Therapy.
  • AIM: To evaluate <sup>68</sup>Ga-PSMA ligand positron-emission tomography-computed tomography (PET/CT)-based radiotherapy for lymph node metastases of prostate cancer after primary therapy.
  • The median pre-treatment prostate-specific antigen (PSA) decreased from 2.75 (range=0.52-8.92) ng/ml to a nadir of 1.37 (range=0.11-8.00) ng/ml (p=0.001) following radiotherapy.
  • Three patients (12.9%) presented with recurrent disease outside the initial radiation field.
  • CONCLUSION: <sup>68</sup>Ga-PSMA ligand PET/CT-based radiotherapy is a promising local treatment option for isolated lymph node metastases of prostate cancer.
  • [MeSH-major] Gallium Radioisotopes / chemistry. Positron Emission Tomography Computed Tomography. Prostatic Neoplasms / diagnostic imaging. Prostatic Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antigens, Surface / chemistry. Glutamate Carboxypeptidase II / chemistry. Humans. Ligands. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prostate-Specific Antigen / blood. Recurrence. Time-to-Treatment. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
  • (PMID = 28314292.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / Gallium Radioisotopes; 0 / Ligands; EC 3.4.17.21 / Glutamate Carboxypeptidase II; EC 3.4.17.21 / glutamate carboxypeptidase II, human; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Keywords] NOTNLM ; PSMA-PET/CT (major topic) / lymph node metastases (major topic) / radiotherapy (major topic) / recurrent prostate cancer (major topic) / systemic therapy (major topic)
  •  go-up   go-down






Advertisement